KAI Pharmaceuticals has initiated enrollment in a Phase I study of KAI-1678, a first-in-class, isozyme-selective inhibitor of the epsilon protein kinase C pathway. KAI-1678 has been shown to be highly effective at reducing pain responses in a wide variety of preclinical pain models.     “Epsilon PKC has been shown to have an important role in both inflammatory and neuropathic pain. KAI-1678 is the first clinical-stage compound that is a specific inhibitor of epsilon PKC,” commented Gregory Be...